Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis Ádám SzélesTamás FazekasTibor Szarvas Review Open access 16 November 2022 Pages: 1061 - 1073
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity Johannes LutzMichael MeisterRegina Heidenreich Research Open access 02 November 2022 Pages: 1075 - 1087
Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy Cleopatra RutihindaRyma HarounAyman J. Oweida Research 03 November 2022 Pages: 1089 - 1102
Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor Yunpeng YaoJianhua LiLiying Wang Research 03 November 2022 Pages: 1103 - 1120
Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer Jianpeng GaoZhenxiong ZhaoHongda Pan Research 07 November 2022 Pages: 1121 - 1138
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells Alistair L. J. SymondsTizong MiaoPing Wang Research Open access 07 November 2022 Pages: 1139 - 1151
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy Katharina H. SusekYsabel A. SchwietzerEvren Alici Research Open access 10 November 2022 Pages: 1153 - 1167
Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model Tianyun QiaoJinbo ZhaoYong Han Research Open access 10 November 2022 Pages: 1169 - 1181
Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model Tianyun QiaoJinbo ZhaoYong Han Correction Open access 26 December 2022 Pages: 1183 - 1183
Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia Kathryn L. WotmanLyndah ChowSteven Dow Research 11 November 2022 Pages: 1185 - 1198
Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy Yun GuPuran ZhangWeijuan Zhang Research Open access 12 November 2022 Pages: 1199 - 1208
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia Andrea KnightMartin PiskacekJiri Mayer Research Open access 14 November 2022 Pages: 1209 - 1224
Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade Aditya JainShijia ZhangAmit A. Kulkarni Research 16 November 2022 Pages: 1225 - 1232
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model Jaya Lakshmi ThangarajSung-Hoon JungJe-Jung Lee Research Open access 16 November 2022 Pages: 1233 - 1246
Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma Marina NinkovCrystal L. SchmerkS. M. Mansour Haeryfar Research 18 November 2022 Pages: 1247 - 1260
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial Cunte ChenSiyang Maggie LiuYangqiu Li Research 24 November 2022 Pages: 1261 - 1272
Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes Prahlad ParajuliRayna RosatiManohar Ratnam Research 25 November 2022 Pages: 1273 - 1284
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer Yoshinori KajiwaraHiroshi TazawaToshiyoshi Fujiwara Research 27 November 2022 Pages: 1285 - 1300
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells Sizhen WangXiaohui ZhangXinbo Wang Research 27 November 2022 Pages: 1301 - 1313
STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma Hao CuiZhou LanGuang-Tao Yu Research 27 November 2022 Pages: 1315 - 1326
Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity Jennie C. KimXian LiuJackson G. Egen Brief Report Open access 17 November 2022 Pages: 1327 - 1335
Correction to: Let‑7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL‑13 and IL‑10 Boxing SuHaibo HanLiqun Zhou Correction 14 February 2023 Pages: 1337 - 1338
Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism Kaikai ZhaoLiyang JiangXiangjiao Meng Correction Open access 21 February 2023 Pages: 1339 - 1341
